NeoGenomics and Oncology

Selected Headlines

Date Headline (link) Source Relevant Snippet
9/9/2021 NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021 FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ('Inivata') alongside collaborators, will present new data on its RaDaR‚N¢ assay for the detection of molecular residual disease (MRD) and recurrence and on its InVisionFirst¬Æ-Lung liquid biopsy test at the European ...
9/9/2021 NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021 FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ("Inivata") alongside collaborators, will present new data on its RaDaR‚N¢ assay for the detection of molecular residual disease (MRD) and recurrence and on its InVisionFirst¬Æ-Lung liquid biopsy test at the European ...
9/9/2021 NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021 FT MYERS, FL 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that its liquid biopsy focused subsidiary Inivata Limited ('Inivata') alongside collaborators, will present new data on its RaDaR‚N¢ assay for the detection of molecular residual disease (MRD) and recurrence and on its InVisionFirst¬Æ-Lung liquid biopsy test at the European Society for ...
9/2/2021 NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Morgan Stanley 19th Annual Global Healthcare Conference, on Tuesday, September 14, 2021 at 10:15am ET.The presentation ...
9/2/2021 NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference FT. MYERS, FL 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Morgan Stanley 19th Annual Global Healthcare Conference, on Tuesday, September 14, 2021 at 10:15am ET.The presentation will be ...
9/1/2021 FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / N FT. MYERS, FL NeoGenomics, Inc. ( NASDAQ:NEO ), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Morgan Stanley 19th Annual Global Healthcare Conference, on Tuesday, September 14, 2021 at 10:15am ET.The presentation will be webcast live ...
9/1/2021 NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Mark Mallon, Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer, and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Morgan Stanley 19th Annual Global Healthcare Conference, on Tuesday, September 14, 2021 at 10:15am ET.The presentation ...
8/31/2021 Global Biliary Tumor Market SWOT Analysis,Key Indicators,Forecast 2027 : NuCana, GlaxoSmithKline, NeoGenomics, Novartis ... NeoGenomics, Novartis, Southwest Oncology Group The report analyses the business environment of the Biliary Tumor. Key market players have been determined or examined allowing identification of company aspects. The overview, subsequent analysis, financial position, and SWOT are some of the elements discussed in this report by the major industry players. The product types covered in the report include: Mecine, Surgery, Other. The application types covered in the report include: Hospitals ...
8/29/2021 EnterCoin Price Reaches $0.0097 on Exchanges (ENTRC) | Daily Political Daily Political NeoGenomics beats Seer on 11 of the 13 factors compared between the two stocks.NeoGenomics Company ProfileNeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical ...
8/14/2021 JPMorgan Chase & Co. Reaffirms Neutral Rating for Sanderson Farms (NASDAQ:SAFM) | Daily Political Daily Political NeoGenomics has higher revenue and earnings than Rennova Health.SummaryNeoGenomics beats Rennova Health on 7 of the 8 factors compared between the two stocks.NeoGenomics Company ProfileNeoGenomics, Inc. is a clinical laboratory company ... testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by ...
8/6/2021 NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter ... NeoGenomics, Inc. (NASDAQ:NEO) (the ' Company ' ), a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2021.'Second-quarter results were strong as all three of our divisions grew significantly year-over-year. Importantly, our core cancer businesses showed meaningful signs of recovery as our clinical business processed record oncology volumes and Pharma Services posted record revenues.' said Mark ...
8/6/2021 The Ridgway Record ... NeoGenomics, Inc. ( NASDAQ:NEO ) (the " Company " ), a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2021."Second-quarter results were strong as all three of our divisions grew significantly year-over-year. Importantly, our core cancer businesses showed meaningful signs of recovery as our clinical business processed record oncology volumes and Pharma Services posted record revenues." said Mark ...
8/6/2021 NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter ... NeoGenomics, Inc. (NASDAQ:NEO) (the ' Company ' ), a leading provider of cancer-focused genetics testing services, today announced its second-quarter results for the period ended June 30, 2021.'Second-quarter results were strong as all three of our divisions grew significantly year-over-year. Importantly, our core cancer businesses showed meaningful signs of recovery as our clinical business processed record oncology volumes and Pharma Services posted record revenues.' said Mark ...
5/11/2021 NeoGenomics To Participate In The Bank of America 2021 Health Care Conference | IT Business Net FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathryn McKenzie, Chief Financial Officer, will be presenting at the Bank of America 2021 Health Care Conference, on Wednesday, May 12, 2021 at 4:15pm ET.The presentation will be webcast live ...
5/11/2021 The Ridgway Record FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. ( NASDAQ:NEO ), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathryn McKenzie, Chief Financial Officer, will be presenting at the Bank of America 2021 Health Care Conference, on Wednesday, May 12, 2021 at 4:15pm ET.The presentation will be webcast live ...
5/10/2021 Roundtable Discussion: Finding Targets for Adjuvant NSCLC Treatment and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved. ‚N¢ Corey J. Langer, MD, led a peer discussion around novel targets for adjuvant non‚Aismall cell lung therapy. Corey J. Langer, MD, director ... a third-party commercial lab. Our community hospital now uses NeoGenomics Laboratories testing. We can retrieve [tissue] and send tests anywhere. A lot of times we‚Aore sending to‚A¶BioReference Laboratories. For patients with ...
5/10/2021 FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGe FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. ( NASDAQ:NEO ), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathryn McKenzie, Chief Financial Officer, will be presenting at the Bank of America 2021 Health Care Conference, on Wednesday, May 12, 2021 at 4:15pm ET.The presentation will be webcast live ...
5/10/2021 NeoGenomics To Participate In The Bank of America 2021 Health Care Conference NeoGenomics To Participate In The Bank of America 2021 Health Care Conference Investor Relations Download as PDF May 10, 2021FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Executive Chairman, Mark Mallon, Chief Executive Officer, and Kathryn McKenzie, Chief Financial Officer, will be presenting at the Bank ...
5/7/2021 NeoGenomics Expects Inivata Buy to Help it Penetrate MRD Monitoring Market May 07, 2021 John Gilmore Premium Save for laterNEW YORK ‚Ai NeoGenomics will use newly acquired Inivata's liquid biopsy technology to further penetrate the cancer genetics testing space by accelerating growth in its own ... companies' existing relationships with pharma and clinical partners in the oncology and pathology space.During a conference call with investors on Wednesday following the announcement and release of NeoGenomics' first quarter earnings, executives from both ...
5/7/2021 People in the News: New Appointments at Helix, Fulgent Genetics, IDbyDNA, Quantum-Si, More ... oncology testing solutions. He most recently served as CMO of NeoGenomics, prior to which he was lab director for Clarient Diagnostic Services.IDbyDNA: Neil Gunn, Guochun LiaoNeil Gunn has been appointed as CEO of pathogen detection firm IDbyDNA, succeeding Guochun Liao, the firm's cofounder, in this role. Gunn joins the company from Roche Diagnostics, where he was president and head of the sequencing business unit. Previously, he led commercial ...
5/6/2021 NeoGenomics to acquire liquid biopsy developer Inivata NeoGenomics to acquire liquid biopsy developer Inivata 10:07) NeoGenomics has agreed to exercise an option granted last year to acquire UK-based commercial-stage liquid biopsy platform company Inivata. Share Article The latest development comes ... shareholders, current NeoGenomics investors and various other investors focusing on oncology.NeoGenomics CEO Mark Mallon said: ‚AuNeoGenomics has spent the better part of the last year working in partnership with the exceptional team of professionals ...
5/6/2021 NeoGenomics to acquire Inivata for $390M after success of lung cancer liquid biopsy collab | FierceBiotech FierceBiotech ... NeoGenomics has opted to cash in on an option in the original deal to acquire the liquid biopsy developer.NeoGenomics will pay $390 million to buy out Inivata, with about $200 million coming from a private placement led by existing Inivata shareholders and NeoGenomics investors, as well as several other oncology-focused investors.The deal is expected to close in June, at which time Inivata‚Aos business will become a ...
5/5/2021 NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform Investor RelationsEstablishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing marketNeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 millionCompletes $200 million strategic financing with leading oncology-focused specialist investorsFT. , genetic testing services and global oncology contract research services, announced today ...
5/5/2021 NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform | 2021-05-05 | Press Releases | Stockhouse Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing marketNeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 millionCompletes $200 million strategic financing with leading oncology-focused specialist investorsFT. MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it ...
5/5/2021 The Ridgway Record Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing marketNeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 millionCompletes $200 million strategic financing with leading oncology-focused specialist investorsFT. MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. ( NASDAQ:NEO ) , a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it ...